Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR)
United Arab Emirates · Delayed Price · Currency is AED 1.020
-0.020 (-1.92%)
At close: Sep 2, 2026
ADX:JULPHAR Income Statement
Financials in millions AED. Fiscal year is January - December.
Millions AED. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,101 | 1,076 | 992.2 | 1,278 | 1,616 | 1,143 | |
Revenue Growth | 7.52% | 8.39% | -22.33% | -20.95% | 41.37% | 99.51% |
Cost of Revenue | 625 | 639.6 | 585.1 | 852.4 | 1,058 | 759.8 |
Gross Profit | 476.3 | 435.9 | 407.1 | 425.1 | 557.9 | 383.4 |
Selling, General & Admin | 361.2 | 357.8 | 346.9 | 458.3 | 596.3 | 451.9 |
Research & Development | 24.8 | 28.2 | 24.5 | - | - | - |
Other Operating Expenses | -4.1 | -4.3 | -10.3 | -8.7 | -9.8 | -110 |
Operating Expenses | 381.9 | 381.7 | 361.1 | 449.6 | 586.5 | 341.9 |
Operating Income | 94.4 | 54.2 | 46 | -24.5 | -28.6 | 41.5 |
Interest Expense | -13.6 | -28.3 | -59.8 | -56.3 | -40.1 | -23.7 |
Interest & Investment Income | 4.7 | 7.6 | 2.6 | 6 | 3.6 | 2.4 |
Earnings From Equity Investments | - | - | - | - | - | -31.4 |
Currency Exchange Gain (Loss) | 0.1 | 0.1 | 0.7 | - | 0.2 | - |
EBT Excluding Unusual Items | 85.6 | 33.6 | -10.5 | -74.8 | -64.9 | -11.2 |
Gain (Loss) on Sale of Investments | 4.4 | 4.4 | 3.3 | 3.5 | 2 | -5.5 |
Asset Writedown | -0.9 | -0.9 | -1.5 | - | - | - |
Other Unusual Items | 10.3 | 10.3 | 2.1 | 1.5 | 29.5 | 59.3 |
Pretax Income | 99.4 | 47.4 | -6.6 | -69.8 | -33.4 | 42.6 |
Income Tax Expense | 4.9 | 3.5 | 2.7 | 6.1 | 2.8 | 1.1 |
Earnings From Continuing Operations | 94.5 | 43.9 | -9.3 | -75.9 | -36.2 | 41.5 |
Earnings From Discontinued Operations | 1.9 | 129.4 | 54.2 | -22.6 | 4.5 | 17.9 |
Net Income to Company | 96.4 | 173.3 | 44.9 | -98.5 | -31.7 | 59.4 |
Minority Interest in Earnings | 0.6 | -1.1 | -0.3 | -0.6 | 2.3 | 5 |
Net Income | 97 | 172.2 | 44.6 | -99.1 | -29.4 | 64.4 |
Net Income to Common | 97 | 172.2 | 44.6 | -99.1 | -29.4 | 64.4 |
Net Income Growth | -45.29% | 286.10% | - | - | - | - |
Shares Outstanding (Basic) | 1,155 | 1,155 | 1,155 | 1,155 | 1,155 | 1,155 |
Shares Outstanding (Diluted) | 1,155 | 1,155 | 1,155 | 1,155 | 1,155 | 1,155 |
Shares Change | - | - | - | - | - | 9.21% |
EPS (Basic) | 0.08 | 0.15 | 0.04 | -0.09 | -0.03 | 0.06 |
EPS (Diluted) | 0.08 | 0.15 | 0.04 | -0.09 | -0.03 | 0.06 |
EPS Growth | -45.29% | 286.11% | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 26.8 | 85.2 | 146.3 | 71.5 | -44.4 | 1.8 |
Free Cash Flow Per Share | 0.02 | 0.07 | 0.13 | 0.06 | -0.04 | 0.00 |
Gross Margin | 43.25% | 40.53% | 41.03% | 33.28% | 34.52% | 33.54% |
Operating Margin | 8.57% | 5.04% | 4.64% | -1.92% | -1.77% | 3.63% |
Profit Margin | 8.81% | 16.01% | 4.50% | -7.76% | -1.82% | 5.63% |
Free Cash Flow Margin | 2.43% | 7.92% | 14.74% | 5.60% | -2.75% | 0.16% |
EBITDA | 135.6 | 98.2 | 138.2 | 74.9 | 66.5 | 128.5 |
EBITDA Margin | 12.31% | 9.13% | 13.93% | 5.86% | 4.12% | 11.24% |
D&A For EBITDA | 41.2 | 44 | 92.2 | 99.4 | 95.1 | 87 |
EBIT | 94.4 | 54.2 | 46 | -24.5 | -28.6 | 41.5 |
EBIT Margin | 8.57% | 5.04% | 4.64% | -1.92% | -1.77% | 3.63% |
Effective Tax Rate | 4.93% | 7.38% | - | - | - | 2.58% |